Premium
Efficacy of combined surgery and 125 I seed brachytherapy for treatment of primary mucoepidermoid carcinoma of the parotid gland
Author(s) -
Wu ZhiYuan,
Wu WenJie,
Zheng Lei,
Huang MingWei,
Shi Yan,
Lv XiaoMing,
Liu ShuMing,
Zhang JianGuo,
Zhang Jie
Publication year - 2019
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.25813
Subject(s) - brachytherapy , medicine , mucoepidermoid carcinoma , parotid gland , confidence interval , hazard ratio , radiation therapy , surgery , carcinoma , urology , oncology , pathology
Abstract Background This study aimed to determine the effectiveness and safety of surgery combined with postoperative 125 I seed brachytherapy for treatment of primary mucoepidermoid carcinoma (MEC) of the parotid gland. Methods Retrospective analysis of data of patients with MEC (n = 108) treated with surgery plus postoperative 125 I seed brachytherapy between 2004 and 2016. Overall survival (OS), disease‐free survival (DFS), local control rate (LCR), distant metastasis, and radiation‐associated toxicities were analyzed, and factors affecting outcomes were evaluated. Results The 5‐ and 10‐year OS were 98.8% and 95.8%, respectively. The DFS and LCR at 5 and 10 years were all 91.4%. Age ≥ 60 years (hazard ratio [HR] = 6.86, 95% confidence interval [CI]: 1.54‐30.55) and T4 disease (HR = 7.15, 95% CI: 1.40‐36.52) were poor prognostic factors. Acute radiation‐associated toxicities were minor. Conclusion Surgery plus 125 I seed brachytherapy appears to be an effective treatment for parotid gland MEC, capable of providing satisfactory outcomes with few complications.